文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

改善临床医生诊断与沟通技能对加泰罗尼亚初级保健急性咳嗽患者抗生素处方适当性的效果与成本效果:ISAAC-CAT整群随机对照试验研究方案

Effectiveness and cost-effectiveness of Improving clinicians' diagnostic and communication Skills on Antibiotic prescribing Appropriateness in patients with acute Cough in primary care in CATalonia (the ISAAC-CAT study): study protocol for a cluster randomised controlled trial.
PubMed 文献 · Trials · 2019-12-17

本研究为整群随机析因对照试验,计划纳入20个初级保健中心、约2940例18岁以上急性下呼吸道感染首次就诊患者,比较常规护理、C反应蛋白检测、沟通技能强化加患者宣传册及联合干预对减少抗生素处方的影响。主要结局为6周内抗生素使用、中重度咳嗽持续时间及质量调整生命年,并开展成本效果与成本效用分析。

要点

  • 试验比较C反应蛋白检测与沟通技能强化两种策略对急性下呼吸道感染抗生素处方的影响。
  • 主要结局包括6周内抗生素使用、中重度咳嗽持续时间和质量调整生命年。
  • 干预组医生和护士接受2小时培训工作坊及每月培训模块。

核心结论

  • ISAAC-CAT项目将评估当前临床指南范围之外的更合理抗生素处方策略的效果与效率。

研究设计与样本

  • 整群随机析因对照试验,计划纳入20个初级保健中心、共2940例患者。
  • 纳入标准为18岁以上因急性下呼吸道感染首次就诊的患者。
  • 中心根据社会经济数据和抗生素消耗量识别,并按层次聚类随机分配到四个试验组。
  • 四个试验组为常规护理、C反应蛋白检测、沟通技能强化加患者宣传册、联合干预。
  • 干预组家庭医生和护士在试验开始前参加2小时培训工作坊,并在试验年度内每月接受干预定制培训模块。

关键数值与推荐

  • 主要结局为6周内抗生素使用、中重度咳嗽持续时间和质量调整生命年。
  • 次要结局包括症状日记测量的疾病持续时间和咳嗽严重程度、再次就诊、住院和并发症。
  • 成本效果和成本效用分析从社会和国家医疗系统角度进行,时间跨度为1年。
  • 医疗成本以2021年欧元表示,将进行单变量和多变量敏感性分析。
  • 将开展两项定性研究(临床 trial 前后)以识别患者期望与担忧及各干预组的障碍与促进因素。

临床怎么用

  • 研究结果可为初级保健中急性下呼吸道感染更合理抗生素处方的策略选择提供证据。
  • 沟通技能强化联合患者宣传册可能作为减少不必要抗生素使用的干预选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite their marginal benefit, about 60% of acute lower respiratory tract infections (ALRTIs) are currently treated with antibiotics in Catalonia. This study aims to evaluate the effectiveness and efficiency of a continuous disease-focused intervention (C-reactive protein [CRP]) and an illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations) on antibiotic prescribing in patients with ALRTIs in Catalan primary care centres. METHODS/DESIGN: A cluster randomised, factorial, controlled trial aimed at including 20 primary care centres (N = 2940 patients) with patients older than 18 years of age presenting for a first consultation with an ALRTI will be included in the study. Primary care centres will be identified on the basis of socioeconomic data and antibiotic consumption. Centres will be randomly assigned according to hierarchical clustering to any of four trial arms: usual care, CRP testing, enhanced communication skills backed up with patient leaflets, or combined interventions. A cost-effectiveness and cost-utility analysis will be performed from the societal and national healthcare system perspectives, and the time horizon of the analysis will be 1 year. Two qualitative studies (pre- and post-clinical trial) aimed to identify the expectations and concerns of patients with ALRTIs and the barriers and facilitators of each intervention arm will be run. Family doctors and nurses assigned to the interventions will participate in a 2-h training workshop before the inception of the trial and will receive a monthly intervention-tailored training module during the year of the trial period. Primary outcomes will be antibiotic use within the first 6 weeks, duration of moderate to severe cough, and the quality-adjusted life-years. Secondary outcomes will be duration of illness and severity of cough measured using a symptom diary, healthcare re-consultations, hospital admissions, and complications. Healthcare costs will be considered and expressed in 2021 euros (year foreseen to finalise the study) of the current year of the analysis. Univariate and multivariate sensitivity analyses will be carried out. DISCUSSION: The ISAAC-CAT project will contribute to evaluate the effectiveness and efficiency of different strategies for more appropriate antibiotic prescribing that are currently out of the scope of the actual clinical guidelines. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03931577.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ruiz R, Moragas A, Trapero-Bertran M, et al. Effectiveness and cost-effectiveness of Improving clinicians' diagnostic and communication Skills on Antibiotic prescribing Appropriateness in patients with acute Cough in primary care in CATalonia (the ISAAC-CAT study): study protocol for a cluster randomised controlled trial. Trials. 2019. PMID: 31847912. doi:10.1186/s13063-019-3727-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。